Michael L. Rankowitz serves as Independent Director of the Company. Mr. Rankowitz has served as a Senior Advisor at Morgan Stanley since 2001. From 1980 to 2001, Mr. Rankowitz was a managing director at Morgan Stanley, where he also served as a co-head of Global High Yield and was responsible for risk management, research and sales for high yield, emerging markets, bank debt and distressed securities. Mr. Rankowitz has held directorships with NF Investment Corp., Carlyle Funds, 1st Tee of Metropolitan New York, Discover Card, Clarent Hospital Corp., New York Racing Authority, International Dyslexia Association —New York Branch, Trinity School (New York) and Browning School (New York). He has a B.S. in Mathematics from the University of Vermont.
As the Independent Director of Veru Inc, the total compensation of Michael Rankowitz at Veru Inc is $53,152. There are 11 executives at Veru Inc getting paid more, with Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. having the highest compensation of $1,426,295.
Michael Rankowitz is 62, he's been the Independent Director of Veru Inc since 2018. There are 1 older and 9 younger executives at Veru Inc. The oldest executive at Veru Inc is Mario Eisenberger, 70, who is the Independent Director.
Michael's mailing address filed with the SEC is 2916 N. MIAMI AVENUE, SUITE 1000, MIAMI, FL, 33127.
Over the last 7 years, insiders at Veru Inc have traded over $5,672,221 worth of Veru Inc stock and bought 673,267 units worth $1,199,518 . The most active insiders traders include Mitchell Shuster Steiner, Harry Fisch e K Gary Barnette. On average, Veru Inc executives and independent directors trade stock every 33 days with the average trade being worth of $22,682. The most recent stock trade was executed by Harry Fisch on 24 May 2024, trading 4,000 units of VERU stock currently worth $5,000.
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Veru Inc executives and other stock owners filed with the SEC include: